Pure Global AI
NCT05372874Not yet recruiting

Treatment of Hepatitis c by Using Direct-acting Antiviral

Evaluation of the Effect of Direct-Acting Antiviral Agents on Melatonin Level in Chronic Hepatitis C Patients in Egypt.
Tanta UniversityClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Hepatitis C
Drug/Device/Intervention
Direct Acting Antivirals
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Tanta University
Timeline & enrollment
Phase
N/A
Start date
May 06, 2022
End date
Jul 30, 2022
Enrollment
50 participants
Primary outcome

Change in malondialdehyde (MDA) level.,Change in melatonin level.

Summary

Patients with hepatitis c showed increased level of oxidative stress. Increased level of
 serum lipid peroxidation leads to the production of toxic mediators as malondialdehyde (MDA)
 which lead to disease progression. Chronic stress shunt tryptophan which is essential amino
 acid toward kynurenic pathway leading to lower level of serotonin and melatonin level.
 Currently, direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C
 virus (HCV).

ICD-10 classifications
Acute hepatitis CChronic viral hepatitis CViral hepatitisChronic viral hepatitisUnspecified viral hepatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05372874
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05372874 through Pure Global AI's free database. This phase not specified trial is sponsored by Tanta University and is currently Not yet recruiting. The study focuses on Hepatitis C. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.